Since targeting therapy against the TME is an excellent opportunity to reduce GBM progression, an additional protein kinase involved in the CFS-1R pathway that could constitute a new therapeutic target is a phosphatidyl-inositol-3 kinase (PI3K). The gene discussed is WEE1; the disease is glioblastoma.